DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-9.81%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$1.55B
AUM Growth
+$1.55B
(+14%)
Cap. Flow
+$361M
Cap. Flow
% of AUM
23.32%
Top 10 Holdings %
Top 10 Hldgs %
50.82%
Holding
63
New
11
Increased
28
Reduced
8
Closed
11
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$75.7M |
| 2 |
Fate Therapeutics
FATE
|
$61.3M |
| 3 |
NovoCure
NVCR
|
$37.3M |
| 4 |
AGEN
Agenus
AGEN
|
$34.4M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$33.2M |
Top Sells
| 1 |
Avidity Biosciences
RNA
|
$23.8M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$17.1M |
| 3 |
Protagonist Therapeutics
PTGX
|
$14.4M |
| 4 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$13.2M |
| 5 |
Atara Biotherapeutics
ATRA
|
$11.8M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Real Estate | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
| $21.8M | 1.4% |
2,652,693
+317,550
| +14% | +$2.61M |
|
27
Viridian Therapeutics
VRDN
$1.5B
| $21.6M | 1.39% |
1,170,290
-166,400
| -12% | -$3.08M |
|
|
SLN
28
Silence Therapeutics
SLN
$227M
| $18.1M | 1.16% |
951,580
+782
| +0.1% | +$14.9K |
|
29
Dianthus Therapeutics
DNTH
$759M
| $15.5M | 1% |
5,359,000
+489,000
| +10% | +$1.42M |
|
|
FMTX
30
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $15.4M | 0.99% |
+1,659,706
| New | +$15.4M |
|
31
Fulcrum Therapeutics
FULC
$351M
| $15.4M | 0.99% |
650,000
-100,000
| -13% | -$2.37M |
|
32
Enanta Pharmaceuticals
ENTA
$180M
| $14.1M | 0.91% |
+198,730
| New | +$14.1M |
|
33
AnaptysBio
ANAB
$569M
| $13.8M | 0.89% |
+558,782
| New | +$13.8M |
|
|
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $12.3M | 0.79% |
2,985,729
+1,213,928
| +69% | +$5M |
|
35
Century Therapeutics
IPSC
$42.5M
| $11.7M | 0.75% |
926,469
+676,469
| +271% | +$8.52M |
|
|
HOOK
36
DELISTED
HOOKIPA Pharma
HOOK
| $11.5M | 0.74% |
+5,035,998
| New | +$11.5M |
|
37
Passage Bio
PASG
$22.7M
| $10.5M | 0.67% |
3,375,000
+158,003
| +5% | +$490K |
|
38
Acumen Pharmaceuticals
ABOS
$82.4M
| $10.2M | 0.65% |
2,599,098
+666,058
| +34% | +$2.6M |
|
|
RXDX
39
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $9.25M | 0.59% |
+245,000
| New | +$9.25M |
|
40
GH Research
GHRS
$837M
| $9.13M | 0.59% |
499,400
| – | – |
|
41
Tenaya Therapeutics
TNYA
$184M
| $6.44M | 0.41% |
546,923
-215,394
| -28% | -$2.54M |
|
42
Assembly Biosciences
ASMB
$190M
| $6.18M | 0.4% |
3,000,000
| – | – |
|
43
Nuvation Bio
NUVB
$1.02B
| $6.08M | 0.39% |
+1,155,492
| New | +$6.08M |
|
|
ATYR
44
aTyr Pharma
ATYR
$527M
| $5.5M | 0.35% |
1,028,515
-71,485
| -6% | -$382K |
|
45
Relmada Therapeutics
RLMD
$37.2M
| $2.76M | 0.18% |
+102,117
| New | +$2.76M |
|
|
VIGL
46
DELISTED
Vigil Neuroscience
VIGL
| $2.74M | 0.18% |
+389,141
| New | +$2.74M |
|
|
VERV
47
DELISTED
Verve Therapeutics
VERV
| $2.34M | 0.15% |
102,342
-397,658
| -80% | -$9.07M |
|
|
AUTL
48
Autolus Therapeutics
AUTL
$399M
| $1.6M | 0.1% |
+382,559
| New | +$1.6M |
|
49
Rafael Holdings
RFL
$51.6M
| $261K | 0.02% |
104,156
-181,558
| -64% | -$455K |
|
50
Acadia Pharmaceuticals
ACAD
$4.38B
| – | – |
0
| – | – |
|